RT Journal Article
SR Electronic
T1 Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 287
OP 293
VO 38
IS 1
A1 SEOL HWA SHIN
A1 SEOK SOON PARK
A1 EUN JIN JU
A1 JIN PARK
A1 EUN JEONG KO
A1 JUNG JIN HWANG
A1 YOUNG-AH SUH
A1 SE JIN JANG
A1 JUNG SHIN LEE
A1 BONG-KOOK KO
A1 KYU-TAE KIM
A1 JONG-SEO LEE
A1 SI YEOL SONG
A1 SEONG-YUN JEONG
A1 EUN KYUNG CHOI
YR 2018
UL http://ar.iiarjournals.org/content/38/1/287.abstract
AB Background/Aim: To maximize success rate for development of HER2-targeted therapeutics, patient-derived xenograft (PDX) models reflecting HER2-positive gastric cancer (HER2+ GC) patients were established. Materials and Methods: GC tissues obtained from surgery of GC patients were implanted into immune-deficient mice, and tumor tissue of HER2+ PDXs were verified of the patient-mimic HER2 expression by immunohistochemistry and explored for the feasibility by testing with Herceptin, the approved therapeutics and novel HER2 antibody therapeutics being developed. Results: We obtained 5 cases of HER2+ GC PDX models reflecting patient's GC tumor, consisting of 2 cases of HER2 3+ and 2 cases of HER2 2+. Novel HER2 antibody displayed significantly improved anti-cancer efficacy in combination with Herceptin. Conclusion: The HER2+ GC PDX models were successfully established to be utilized for preclinical evaluation of HER2-targeting drugs and combined therapies for GC treatment, as an ideal platform of personalized tools for precision therapy.